Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service PFO & septal closure cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 96% on average (6 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 238 | 48% |
| 2020 | 0 | 203 | 50% |
| 2021 | 2 | 274 | 52% |
Patent foramen ovale and atrial septal defect closure: mostly patients under 65. Professional codes (what the surgeon bills): CPT 93580.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in California; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 2 | 121+7.6%/yr | +7.6%/yr | 0.2 | 0% | 170 in 2030+5.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 390 | 17,678−4.1%/yr | −4.1%/yr | 4.30.9× | 0% | 19,700 in 2030+1.8%/yr |
| Structural heart (TAVR, TEER) |
PFO & septal closure in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
| 2024 |
| 312 |
| 56% |
| 2025 est. | ≈ 190 | – |
| 2026 est. | ≈ 190 | – |
| 2022 | 0 | 243 | 53% |
| 2023 | 1 | 260 | 55% |
| 2024 | 5 | 312 | 56% |
| 2025 from claims | – | 186 150–218 | 56% |
| 2026 forecast | – | 189 148–237 | 56% |
| 2027 forecast | – | 191 142–253 | 56% |
| 2028 forecast | – | 194 137–267 | 56% |
| 2029 forecast | – | 196 133–281 | 57% |
| 2030 forecast | – | 198 130–294 | 57% |
In 2025, 100% hospital outpatient.
| 238 |
| 5,995+3.6%/yr |
| +3.6%/yr |
| 1.50.9× |
| 0% |
| 8,310 in 2030+5.6%/yr |
| Mechanical circulatory support | 3 | 1,597−4.2%/yr | −4.2%/yr | 0.51.1× | 0% | 1,700 in 2030+1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 54% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 2 companies reported engagement with California’s surgeons worth $247K in consulting, speaking, meals and travel tied to these products, about $49K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.